The Dow Jones Industrial Average rose 317.24 points, or 0.71%, to 44,873.28, the S&P 500 rose 23.60 points, or 0.39%, to ...

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

Wall Street struggled for direction and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed ...

"We think the leaders of other countries don't really understand Trump's art of the deal," said Jay Hatfield, CEO and ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Denmark may curb exports of weight loss drugs Ozempic and Wegovy, as well as Lego, if Trump plans to buy Greenland. Tariffs ...

Santiago Buitrago won the second stage of the Tour of Valencia. The Colombian of Bahrain-Victorious was the strongest after a ...

Although he has a long background with this strategy and the ... fueled by strong showings from top-10 holdings Alphabet, Meta, and Novo Nordisk, as well as a much-lesser-known name also in ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...